308 related articles for article (PubMed ID: 15041052)
1. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
[TBL] [Abstract][Full Text] [Related]
2. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma.
Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR
J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia.
Polkowski WP; Skomra DG; Mielko J; Wallner GT; Szumiło J; Zinkiewicz K; Korobowicz EM; van Lanschot JJ
Eur J Surg Oncol; 2004 Dec; 30(10):1084-92. PubMed ID: 15522555
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
6. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
Gynecol Oncol; 2001 Jan; 80(1):67-73. PubMed ID: 11136572
[TBL] [Abstract][Full Text] [Related]
7. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
9. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma.
Yokoyama Y; Hiyama E; Murakami Y; Matsuura Y; Yokoyama T
Cancer; 1999 Nov; 86(9):1691-9. PubMed ID: 10547541
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.
Ashida K; Terada T; Kitamura Y; Kaibara N
Hepatology; 1998 Apr; 27(4):974-82. PubMed ID: 9537436
[TBL] [Abstract][Full Text] [Related]
11. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of CD44s expression in biliary tract cancers.
Lee SM; Lee KE; Chang HJ; Choi MY; Cho MS; Min SK; Lee HK; Mun YC; Nam EM; Seong CM; Lee SN
Ann Surg Oncol; 2008 Apr; 15(4):1155-60. PubMed ID: 18214619
[TBL] [Abstract][Full Text] [Related]
13. E-Cadherin and CD44 expression in cervical intraepithelial neoplasia: comparison between HIV-positive and HIV-negative women and correlation with HPV status.
Daraï E; Walker-Combrouze F; Bénifla JL; Hénin D; Feldmann G; Madelenat P; Scoazec JY
Gynecol Oncol; 2000 Jan; 76(1):56-62. PubMed ID: 10620442
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx.
Rodrigo JP; Domínguez F; Alvarez C; González MV; Herrero A; Suárez C
Am J Clin Pathol; 2002 Jul; 118(1):67-72. PubMed ID: 12109858
[TBL] [Abstract][Full Text] [Related]
15. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma.
Hong RL; Pu YS; Hsieh TS; Chu JS; Lee WJ
J Urol; 1995 Jun; 153(6):2025-8. PubMed ID: 7538603
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
[TBL] [Abstract][Full Text] [Related]
19. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in carcinoid tumors.
Sun X; Gong Y; Talamonti MS; Rao MS
Mod Pathol; 2002 Dec; 15(12):1333-8. PubMed ID: 12481015
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
